Profil
Mr. Xiao Ming Zhang is Independent Non-Executive Director at Mingyuan Medicare Development Co. Ltd.
He is on the Board of Directors at Mingyuan Medicare Development Co. Ltd.
He received his undergraduate degree from the University of Manchester Institute of Science & Technology, a graduate degree from the University of Oxford, and a graduate degree from the London School of Economics & Political Science.
Anciens postes connus de Xiao Ming Zhang
| Sociétés | Poste | Fin |
|---|---|---|
| MINGYUAN MEDICARE DEVELOPMENT CO., LTD. | Directeur/Membre du Conseil | 20/05/2016 |
Formation de Xiao Ming Zhang
| University of Oxford | Graduate Degree |
| London School of Economics & Political Science | Graduate Degree |
| University of Manchester Institute of Science & Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Mingyuan Medicare Development Co. Ltd.
 Mingyuan Medicare Development Co. Ltd. BiotechnologyHealth Technology Mingyuan Medicare Development Co. Ltd. engages in provision of medicare solutions for the early detection and prevention of diseases particularly in China. It operates through the following segments: Protein Chips, Healthcare, Medical Centers Management, Individualized Target Therapy, and Bio-Drugs. The Protein Chips segment manufactures and distributes C-12 products to hospitals, medical centers, and life insurance companies in China. The Healthcare segment engages in the provision of sales and marketing campaign for HPV DNA testing kits and making important progress to register products for distribution to female patients at hospitals nationwide. The Medical Centers Management segment engages in the provision of healthcare services for residents living in cities. The Individualized Target Therapy segment specializes in molecular diagnostic kits for leukemia, lymphoma and individualised target cancer therapy. The Bio-Drugs segment engages in the development, production and commercialization of a new generation of non-specific nanotechnology immunomodulatory drugs known as non-cell Corynebacterium pavum products. The company was founded on May 8, 1989 and is headquartered in Hong Kong. | Health Technology |
